Kalaris Therapeutics Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Kalaris Therapeutics Inc
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
/ 
Frequently asked questions
To buy Kalaris Therapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Kalaris Therapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Kalaris Therapeutics Inc is KLRS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Kalaris Therapeutics Inc has its primary listing on NASDAQ. You can trade Kalaris Therapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Kalaris Therapeutics Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Kalaris Therapeutics Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Kalaris Therapeutics Inc.